Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Asthma is a common disease in childhood with a minority of affected children suffering from severe asthma. Patients with severe asthma require high dose inhaled glucocorticoids plus a second controller and/or systemic corticosteroids to be well-controlled or remain uncontrolled despite such treatment. Although only a small subset of children and adolescents falls in this category, the management of affected patients represents a major concern for pediatricians. Guidelines and recommendations have been designed to guide the management of this group of patients. Though the terms "recommendations" and "guidelines" are often used interchangeably, it should be noted that the first one should be used more narrowly to identify specific actions and the second one to broadly refer to the umbrella under which multiple recommendations for a specific condition are provided. Moreover, the availability of several and sometimes-conflicting documents on severe asthma management both in adult and pediatric age could generate confusion among health care professionals. The manuscript analyses seven papers addressing severe asthma, comparing any key aspects and differences. Finally, we tried to create a more practical document for physicians to simplify the interpretation of the several available documents on severe asthma management focusing the pediatric age.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ppul.26387DOI Listing

Publication Analysis

Top Keywords

severe asthma
24
children adolescents
8
practical document
8
document physicians
8
documents severe
8
asthma management
8
pediatric age
8
severe
6
asthma
6
asthma guidelines
4

Similar Publications

Can immunotherapy prevent the progression of airway disease?

Curr Opin Allergy Clin Immunol

August 2025

Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.

Purpose Of Review: The potential of allergen immunotherapy (AIT) to prevent allergic airway disease progression are demonstrated. Though not all patients benefit equally, there is limited research on which patients may benefit most.In this article, we focus on factors that may influence the risk of progression and their influence on the preventive effects of AIT, and whether some patients may benefit more than others may.

View Article and Find Full Text PDF

Introduction: Food-induced anaphylactic shock is the most severe and life-threatening manifestation of food allergy in children. However, its underlying risk factors remain poorly defined, especially in pediatric populations. This study aimed to identify independent predictors of food-induced anaphylactic shock by analyzing clinical and immunological data from a tertiary hospital in Northern China.

View Article and Find Full Text PDF

Background: Although the benefits of biologics in severe asthma are well established, the optimal strategy to discontinue therapy remains controversial.

Aim: to evaluate clinical, functional, and laboratory course of children and adolescents with severe asthma after biological therapy withdrawal due to sustained good control. Secondary aim was to identify clinical or inflammatory markers predictive of asthma control after discontinuation.

View Article and Find Full Text PDF

Introduction: Chronic rhinosinusitis with nasal polyp (CRSwNP) is a predominant type 2 inflammatory disease, affecting the sense of smell and quality of life. Loss of smell compromises physical and emotional health, creating negative impacts and its treatment in CRSwNP is challenging.

Aim: To present the outcomes of dupilumab in olfactory function, Nasal Polyp Score (NPS) and quality of life in Brazilian patients with severe CRSwNP.

View Article and Find Full Text PDF

Systematic Literature Review of Real-world Outcomes of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis.

J Allergy Clin Immunol Pract

September 2025

Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health, Denver, Colorado, USA. Electronic address:

Background: Several real-world cohorts and numerous case reports investigating benralizumab outcomes in eosinophilic granulomatosis with polyangiitis have been published. These studies complement the limited clinical trial data available by providing early insights on benralizumab use in a broader, real-world population.

Objective: The objective of this systematic literature review (SLR) was to provide an overview of the real-world outcomes of benralizumab in EGPA.

View Article and Find Full Text PDF